

Irish Haemophilia Society
Annual Report and Financial Statements
for the financial year ended 31 December 2023

Howlin, O'Rourke Auditors & Accountants Limited
T/a Howlin O'Rourke & Co
Certified Public Accountants & Statutory Audit Firm
4, The Seapoint Building
Clontarf
Dublin 3

Company Number: 142834

Irish Haemophilia Society

CONTENTS

	Page
Directors and Other Information	3
Directors' Report	4 - 5
Directors' Responsibilities Statement	6
Independent Auditor's Report	7 - 8
Appendix to the Independent Auditor's Report	9
Income and Expenditure Account	10
Balance Sheet	11
Reconciliation of Members' Funds	12
Cash Flow Statement	13
Notes to the Financial Statements	14 - 18
Supplementary Information	20 - 22

Irish Haemophilia Society DIRECTORS AND OTHER INFORMATION

Directors	Ms. Aislinn Farrelly Mr. Donal McCann (Resigned 2 November 2023) Mr. Daniel McIntyre Ms. Breda Quealy Mr. Paul Dunne Ms. Barbara Wynne Mr. John Stack Mr. Seamus McDonald Ms. Mary-Clare Delaney Mr. James O'Leary
Company Secretary	Ms. Barbara Wynne
Company Number	142834
Charity Number	20023041
Registered Office and Business Address	1st Floor Cathedral Court New Street, Dublin 8 D08 VH64
Auditors	Howlin, O'Rourke Auditors & Accountants Limited T/a Howlin O'Rourke & Co Certified Public Accountants & Statutory Audit Firm 4, The Seapoint Building Clontarf Dublin 3
Bankers	Allied Irish Bank Capel Street Dublin 1

Irish Haemophilia Society

DIRECTORS' REPORT

for the financial year ended 31 December 2023

The directors present their report and the audited financial statements for the financial year ended 31 December 2023.

Principal Activity

The principal activity of the company is to offer support, advice and aid for sufferers of haemophilia and other related bleeding disorders and their families.

The Company is limited by guarantee not having a share capital.

Principal Risks and Uncertainties

The Directors consider that the following are the principal risk factors that could materially and adversely affect the company's future financial position:

- Rising costs across the board without a corresponding increase in core funding.
- Rise in cost-of-living presenting challenges for recruitment and retention of staff.
- Decline in government funding.

Financial Results

The deficit for the financial year after providing for depreciation amounted to €(14,626) (2022 - €(65,853)).

At the end of the financial year, the company has assets of €2,528,439 (2022 - €2,465,970) and liabilities of €133,704 (2022 - €86,609). The net assets of the company have increased by €15,374.

Directors and Secretary

The directors who served throughout the financial year, except as noted, were as follows:

Ms. Aislinn Farrelly
Mr. Donal McCann (Resigned 2 November 2023)
Mr. Daniel McIntyre
Ms. Breda Quealy
Mr. Paul Dunne
Ms. Barbara Wynne
Mr. John Stack
Mr. Seamus McDonald
Ms. Mary-Clare Delaney
Mr. James O'Leary

The secretary who served throughout the financial year was Ms. Barbara Wynne.

In accordance with the Constitution, the directors retire by rotation and, being eligible, offer themselves for re-election.

Post Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

Auditors

The auditors, Howlin, O'Rourke Auditors & Accountants Limited, (Certified Public Accountants & Statutory Audit Firm) have indicated their willingness to continue in office in accordance with the provisions of section 383(2) of the Companies Act 2014.

Statement on Relevant Audit Information

In accordance with section 330 of the Companies Act 2014, so far as each of the persons who are directors at the time this report is approved are aware, there is no relevant audit information of which the statutory auditors are unaware. The directors have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and they have established that the statutory auditors are aware of that information.


Irish Haemophilia Society
DIRECTORS' REPORT

for the financial year ended 31 December 2023


Accounting Records

To ensure that adequate accounting records are kept in accordance with sections 281 to 285 of the Companies Act 2014, the directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the company's office at 1st Floor, Cathedral Court, New Street, Dublin 8, D08 VH64.

Signed on behalf of the board


Mr. Daniel McIntyre
Director

2 March 2024


Ms. Barbara Wynne
Director

2 March 2024

Irish Haemophilia Society DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 December 2023

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.


Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.


The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014 and enable the financial statements to be readily and properly audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board



Ms. Daniel McIntyre
Director

2 March 2024



Ms. Barbara Wynne
Director

2 March 2024

INDEPENDENT AUDITOR'S REPORT

to the Members of Irish Haemophilia Society

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Irish Haemophilia Society ('the company') for the financial year ended 31 December 2023 which comprise the Income and Expenditure Account, the Balance Sheet, the Reconciliation of Members' Funds, the Cash Flow Statement and the related notes to the financial statements, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", issued in the United Kingdom by the Financial Reporting Council, applying Section 1A of that Standard.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2023 and of its deficit for the financial year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the Provisions Available for Audits of Small Entities, in the circumstances set out in note 4 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

INDEPENDENT AUDITOR'S REPORT

to the Members of Irish Haemophilia Society

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

Respective responsibilities

Responsibilities of directors for the financial statements

As explained more fully in the Directors' Responsibilities Statement set out on page 6, the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, if applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operation, or has no realistic alternative but to do so.


Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is contained in the appendix to this report, located at page 9, which is to be read as an integral part of our report.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume any responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



Myra Finnegan

for and on behalf of

HOWLIN, O'ROURKE AUDITORS & ACCOUNTANTS LIMITED

T/A HOWLIN O'ROURKE & CO

Certified Public Accountants & Statutory Audit Firm

4, The Seapoint Building

Clontarf

Dublin 3

2 March 2024

Irish Haemophilia Society

APPENDIX TO THE INDEPENDENT AUDITOR'S REPORT

Further information regarding the scope of our responsibilities as auditor

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Irish Haemophilia Society
INCOME AND EXPENDITURE ACCOUNT
for the financial year ended 31 December 2023

	Notes	2023 €	2022 €
Income		724,479	688,796
Expenditure		<u>(759,422)</u>	<u>(715,721)</u>
Deficit before interest		(34,943)	(26,925)
Other gains and losses	6	<u>20,317</u>	<u>(38,928)</u>
Deficit before tax		<u><u>(14,626)</u></u>	<u><u>(65,853)</u></u>

Approved by the board on 2 March 2024 and signed on its behalf by:


Mr. Daniel McIntyre
Director


Ms. Barbara Wynne
Director

Irish Haemophilia Society


BALANCE SHEET


as at 31 December 2023

	Notes	2023 €	2022 €
Fixed Assets			
Tangible assets	8	1,011,283	1,051,678
Investments	9	342,495	322,178
		<u>1,353,778</u>	<u>1,373,856</u>
Current Assets			
Debtors	10	21,824	10,767
Cash and cash equivalents		1,152,837	1,081,347
		<u>1,174,661</u>	<u>1,092,114</u>
Creditors: amounts falling due within one year	12	(133,704)	(86,609)
Net Current Assets		<u>1,040,957</u>	<u>1,005,505</u>
Total Assets less Current Liabilities		<u>2,394,735</u>	<u>2,379,361</u>
Reserves			
Capital reserves and funds		273,220	243,220
Income and expenditure account		2,121,515	2,136,141
Members' Funds		<u>2,394,735</u>	<u>2,379,361</u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

Approved by the board on 2 March 2024 and signed on its behalf by:


Mr. Daniel McIntyre
Director


Ms. Barbara Wynne
Director

Irish Haemophilia Society
RECONCILIATION OF MEMBERS' FUNDS
as at 31 December 2023

	Retained Sinking Fund surplus		Total
	€	€	€
At 1 January 2022	2,201,994	223,220	2,425,214
Deficit for the financial year	(65,853)	-	(65,853)
Other movements in Members' Funds	-	20,000	20,000
At 31 December 2022	2,136,141	243,220	2,379,361
Deficit for the financial year	(14,626)	-	(14,626)
Other movements in Members' Funds	-	30,000	30,000
At 31 December 2023	2,121,515	273,220	2,394,735

Irish Haemophilia Society
CASH FLOW STATEMENT
for the financial year ended 31 December 2023

	Notes	2023 €	2022 €
Cash flows from operating activities			
Deficit for the financial year		(14,626)	(65,853)
Adjustments for:			
Fair value gains and losses		(20,317)	38,928
Depreciation		40,395	40,395
		<u>5,452</u>	<u>13,470</u>
Movements in working capital:			
Movement in debtors		(11,057)	(573)
Movement in creditors		77,095	25,193
		<u>71,490</u>	<u>38,090</u>
Cash flows from investing activities			
Payments to acquire tangible assets		-	(10,479)
			<u>(10,479)</u>
Net increase in cash and cash equivalents		71,490	27,611
Cash and cash equivalents at beginning of financial year		1,081,347	1,053,736
Cash and cash equivalents at end of financial year	11	<u>1,152,837</u>	<u>1,081,347</u>

Irish Haemophilia Society

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2023

1. General Information

Irish Haemophilia Society is a company limited by guarantee incorporated in Ireland

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 December 2023 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The Directors consider it prudent to retain a provision of €50,000 at this time in relation to the general area of professional fees.

The Government introduced a Vat compensation scheme for Charities. The Irish Haemophilia Society received a refund in 2023 in the sum of €567 which was offset against unrecoverable vat in the amount of €27,690 resulting in a net unrecoverable vat in the sum of €27,123 (2022 €24,322).

The Directors made a provision of €30,000 in 2023 to the Building Sinking Fund to allow for future possible capital costs in relation to the Headquarters or the Society Member Accommodation Facility.

Corporate Donations income 2019 included a once off grant payment of €50,000 towards the cost of the purchase of a house or apartment by the Irish Haemophilia Society for the purpose of its members'. In 2021 the Irish Haemophilia Society purchased an Apartment at 65/65A Hyde Square Dublin 8 and this grant was offset against the total cost of €430,528 resulting in a net cost of €380,528 as outlines in note 8.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Income

Income represents total Grants and other income received for the year as outlined on page 20.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-	2% Straight line
Fixtures, fittings and equipment	-	20% Straight Line

Investment properties

Investment property is property held either to earn rental income, or for capital appreciation (including future re-development) or for both, but not for sale in the ordinary course of business.

Investment property is initially measured at cost, which includes the purchase cost and any directly attributable expenditure. Investment property is subsequently valued at its fair value at each reporting date, by professional external valuers. The difference between the fair value of an investment property at the reporting date and its carrying value prior to the valuation is recognised in the Income and Expenditure Account as a fair value gain or loss. Any gain or loss on disposal of an investment property (calculated as the difference between the net proceeds from disposal and the carrying amount of the item) is recognised in the Income and Expenditure Account.

Irish Haemophilia Society

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2023

Investments

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the income and expenditure account in the year in which it is receivable.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

Taxation

The Irish Haemophilia Society is a registered Charity and is exempt from Corporation Tax.

Research and development

3. Departure from Companies Act 2014 Presentation

The directors have elected to present an Income and Expenditure Account instead of a Profit and Loss Account in these financial statements as this company is a not-for-profit entity.

4. Provisions Available for Audits of Small Entities

In common with many other businesses of our size and nature, we use our auditors to assist with the preparation of the financial statements.

5.	Operating deficit	2023 €	2022 €
	Operating deficit is stated after charging:		
	Depreciation of tangible assets	40,395	40,395
		<u> </u>	<u> </u>

6.	Other Gains and Losses	2023 €	2022 €
----	------------------------	-----------	-----------

Fair value gains and losses are as follows:

	Investments in shares	20,317	(38,928)
		<u> </u>	<u> </u>

7. Employees

The average monthly number of employees, including directors, during the financial year was 6, (2022 - 6). The Directors did not receive salary in 2023 or 2022.

Irish Haemophilia Society
NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2023

8. Tangible assets	Land and buildings	Land and buildings	Land and buildings	Fixtures and fittings	Fixtures and fittings	Fixtures and fittings	Office equipment	Total
	€	€	€	€	€	€	€	€
Cost or Valuation								
At 1 January 2023	1,314,079	380,528	175,000	15,339	90,365	94,014	2,069,325	
At 31 December 2023	1,314,079	380,528	175,000	15,339	90,365	94,014	2,069,325	
Depreciation								
At 1 January 2023	736,747	15,222	75,250	15,339	90,365	84,724	1,017,647	
Charge for the financial year	26,282	7,611	3,500	-	-	3,002	40,395	
At 31 December 2023	763,029	22,833	78,750	15,339	90,365	87,726	1,058,042	
Net book value								
At 31 December 2023	551,050	357,695	96,250	-	-	6,288	1,011,283	
At 31 December 2022	577,332	365,306	99,750	-	-	9,290	1,051,678	

The property located on the 1st Floor, Cathedral Court, New Street, Dublin 8 was acquired at a cost of €2,014,079 in 2006. The Directors increased the property depreciation from 2% to 5% in 2012. As property prices have increased in the previous twelve months and the Irish Haemophilia Society obtained external property valuations in April 2016 totalling €1,745,000, the Directors decided to decrease the depreciation to 2% in 2019. The property net book value per the Financial Statements as at 31st December 2023 is €1,004,995, which is significantly below fair value. It is therefore not deemed necessary to impair further. This will be reviewed on an annual basis.

Irish Haemophilia Society
NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2023

9. Investments

	Listed investments	Total
	€	€
Investments Cost or Valuation		
At 1 January 2023	322,178	322,178
Revaluations	20,317	20,317
	<u>342,495</u>	<u>342,495</u>
At 31 December 2023		
Net book value		
At 31 December 2023	<u>342,495</u>	<u>342,495</u>
At 31 December 2022	<u>322,178</u>	<u>322,178</u>

10. Debtors

	2023	2022
	€	€
Prepayments\Accrued Income	<u>21,824</u>	<u>10,767</u>

11. Cash and cash equivalents

	2023	2022
	€	€
Cash and bank balances	<u>1,152,837</u>	<u>1,081,347</u>

**12. Creditors
Amounts falling due within one year**

	2023	2022
	€	€
Taxation	9,746	9,291
Other creditors	4,330	7,548
Accruals	119,628	69,770
	<u>133,704</u>	<u>86,609</u>

13. Status

The liability of the members is limited.

Every member of the company undertakes to contribute to the assets of the company in the event of its being wound up while they are members or within one year thereafter for the payment of the debts and liabilities of the company contracted before they ceased to be members and the costs, charges and expenses of winding up and for the adjustment of the rights of the contributors among themselves such amount as may be required, not exceeding € 2.

14. Capital Reserves and Funds

The sum of €30,000 was allocated to the Sinking Fund in 2023.

Irish Haemophilia Society

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2023

15. Related party transactions

Key management includes the Board of Directors, all members of the Company Management and the Company Secretary. The compensation paid or payable to key management for employee services is shown below:

	2023 €	2022 €
Key management compensation		
Salaries and other short-term employee benefits	131,444	127,965
Post - employment benefits	36,476	35,312

The Directors and Company Secretary did not receive any compensation in 2023 or 2022.

Brian O'Mahony CEO of the Irish Haemophilia Society is also a Director of Cladec Management Limited. The sum of €10,062 was received by the Irish Haemophilia Society for external work carried out by Cladec Management Limited during 2023. This sum was reimbursed to the company.

16. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

17. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 2 March 2024.

IRISH HAEMOPHILIA SOCIETY

SUPPLEMENTARY INFORMATION

RELATING TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

NOT COVERED BY THE AUDITORS REPORT

THE FOLLOWING PAGES DO NOT FORM PART OF THE AUDITED FINANCIAL STATEMENTS

Irish Haemophilia Society
SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS
TRADING STATEMENT
for the financial year ended 31 December 2023

	Schedule	2023 €	2022 €
Income			
Health Service Executive		595,125	575,000
Membership		3,100	2,940
Donations - Members		27,467	24,174
Donations - Corporate		90,969	81,000
Fundraising		2,218	2,601
H.H.T Trust		5,600	-
Twining		-	3,081
		<u>724,479</u>	<u>688,796</u>
Overhead expenses	1	<u>(759,422)</u>	<u>(715,721)</u>
		<u>(34,943)</u>	<u>(26,925)</u>
Miscellaneous income	2	<u>20,317</u>	<u>(38,928)</u>
Net deficit		<u><u>(14,626)</u></u>	<u><u>(65,853)</u></u>

Irish Haemophilia Society
SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS
SCHEDULE 1 : OVERHEAD EXPENSES
for the financial year ended 31 December 2023

	2023 €	2022 €
Administration Expenses		
Wages and Salaries	280,970	266,386
Employers Prsi Contributions	31,276	29,428
Pension Costs	43,887	42,189
Services Charges & Insurance	9,967	25,894
Light, Heat & Services	13,651	13,123
Help To Members	8,603	8,545
Subscriptions	1,717	1,781
Educational Grants	15,550	17,350
Twinning- Jordan/Vietnam Development Work	36	1,959
HQ Costs	6,443	5,605
Office Expenses, Stationery etc.	4,795	12,939
I.H.S Members' Facility	(43)	9,543
Post, Publications & Photocopying	27,939	22,928
Telephone/Internet	4,100	4,220
Website	5,315	3,154
Computer Services	19,057	21,934
Meeting Expenses	19,194	19,429
Safety/Supply Activities	147	291
A.G.M & Annual Conference	50,237	37,285
Information & Support Conferences/Meetings	9,919	7,733
Members' Conference	46,211	54,173
Ageing Conference	-	11,561
Parents' Conference	29,861	-
Women with Bleeding Disorders Conference	8,982	-
Legal and Professional	500	-
Sponsorship/Training	1,016	1,613
Unrecoverable Vat	27,123	24,322
Bank Charges	1,931	2,101
General Expenses	14,528	4,225
Provision for Sinking Fund	30,000	20,000
Auditor's Remuneration	6,115	5,615
Depreciation of Tangible Assets	40,395	40,395
	<hr/>	<hr/>
Total Overheads	759,422	715,721
	<hr/> <hr/>	<hr/> <hr/>

Irish Haemophilia Society
SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS
SCHEDULE 2 : MISCELLANEOUS INCOME
for the financial year ended 31 December 2023

	2023 €	2022 €
Miscellaneous Income		
Other gains and losses	<u>20,317</u>	<u>(38,928)</u>

Irish Haemophilia Society

INFORMATION RELATING TO THE GOVERNMENTS GRANTS

For the year ended 31st December 2023


GRANTS AND OTHER INFORMATION


Name of State Agency	Health Service Executive
Grant Programme	HSE Revenue Grant
Purpose of the Grant	Pay and General Administration
Total Grant	€575,000
Grant taken to Income in the period	€575,000
The cash received in the period	€575,000
Grant amounts deferred at the period end	€0
Expenditure	€575,000
Term	Expires 31 st December 2023
Received year end	31 st December 2023
Capital Grant	Nil
Restriction on use	Support for staff wages and operating costs
Tax Clearance	Yes

The Company is compliant with the relevant Circulars, including Circular 13/2014. There was one employee in receipt of a salary between €70,000 and €80,000 during the year. The Irish Haemophilia Society is over 50% funded from Exchequer Funding.

Signed on behalf of the board


Mr. Daniel McIntyre
Director


Ms. Barbara Wynne
Director


Myra Finnegan
HOWLIN O'ROURKE AUDITORS & ACCOUNTANTS LTD
T/a Howlin O'Rourke & Co
Certified Public Accountants & Statutory Audit Firm
Unit 4
4 The Seapoint Building
Clontarf
Dublin 3

Date: 2 March 2024